Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—Natera announced a second research collaboration with Denmark’s Aarhus University utilizing the company’s research use only technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients. (The university will also use the Signatera technology in a bladder cancer study.)
December 2017—Olympus released its IXplore SpinSR10 imaging system, which aims to balance speed, resolution, and efficiency in a single, flexible platform. A high frame rate and 120 nm XY resolution enable researchers to observe the fine details and workings of internal cellular structures while offering the ability to switch between super-resolution, confocal, and wide-field imaging modes.
November 2017—Beckman Coulter Diagnostics received CE mark clearance for a high-sensitivity troponin assay that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.
November 2017—DiaSorin Molecular announced the U.S. introduction of the Simplexa C. difficile Direct Assay upon receiving clearance from the Food and Drug Administration.
November 2017—Natera announced that its Panorama noninvasive prenatal test is validated to screen twin pregnancies for zygosity and chromosomal abnormalities. Panorama can tell the difference between the mother’s and the baby’s DNA, enabling it to distinguish between each twin’s DNA.
November 2017—The CW3 Cell Washer, from Thermo Scientific, is an FDA-cleared, fully automated, high-performance cell washer designed to enable precise, thorough, reproducible, and rapid blood cell washing of up to 24 tubes in a three-minute run.
November 2017—Meridian Life Science launched its next-generation active human anti-mouse antibody (HAMA) blocker, TruBlock Ultra. It works over several assay types and blocks interference created by HAMA, rheumatoid factor, and heterophilic antibodies.
November 2017—Ortho Clinical Diagnostics received FDA approval for the Vitros Immunodiagnostic Products HBeAg Assay and the Vitros Anti-HBe Assay for use on the Vitros 3600 Immunodiagnostic System and 5600 Integrated System.
November 2017—Rosetta Genomics entered into a definitive agreement in early September to sell all of its ownership interest in PersonalizeDx to Pragmin Prognosis.
November 2017—Agilent Technologies announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the FDA for use as an aid in identifying gastric or gastroesophageal junction adenocarcinoma patients for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck.
